Ask about this productRelated genes to: NEFL antibody
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL antibody
Related articles to: NEFL antibody
- Blood-based neural biomarkers linked to aging may provide insights into the biological end point of the human lifespan. However, the key biomarker associated with cognition and mortality in centenarians remains unclear. - Source: PubMed
Publication date: 2026/05/01
Shikimoto RyoSasaki TakashiAbe YukikoTai KenjiHirose NobuyoshiOkano HideyukiArai Yasumichi - The repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). While neurofilament light chain (NEFL) is an established biomarker of neuroaxonal damage, its specific dose-response relationship with the expansion and its potential role beyond a passive bystander require systematic investigation. We performed a proteome-wide screen to identify plasma proteins linked to the expansion and evaluated their predictive value for motor neuron disease (MND). - Source: PubMed
Publication date: 2026/04/21
Hu ZhenWan Jing-JinYan Qin-QinFan YuLiu Jun - Prospective studies of blood-based biomarkers reflecting pathogenic processes, other than Alzheimer-specific pathologies, that contribute to dementia in diverse cohorts are lacking. - Source: PubMed
Shrestha SrishtiZhu XiaoqianWindham B GwenSullivan Kevin JPalta PriyaGottesman Rebecca FTracy Russell PJack Clifford RCogswell Petrice MVemuri PrashanthiSeshadri SudhaMosley Thomas HGriswold Michael EFornage Myriam - Several anticancer drugs can cause chemotherapy-induced peripheral neurotoxicity (CIPN) in approximately 70% of patients; of these, 30% continue to have chronic symptoms hampering quality of life. As more people live with and beyond cancer therapy, it is becoming increasingly important for clinicians to assess those at higher risk of CIPN and provide care for managing CIPN severity. Biomarkers could be appropriate in this regard. However, an initial step towards biomarker-informed care is to advance scientific knowledge regarding the potential of current biomarkers such as neurofilament light chain (NfL). Here, outcomes of a CIPN biomarker workshop and discussions among clinical and scientific experts held during the MASCC 2024 annual conference are reported. The aims of this work are to (1) identify knowledge gaps regarding the potential for serum NfL (sNfL) as a predictive CIPN biomarker, (2) provide guidance for future biomarker research, and (3) explore whether sNfL is ready for use in clinical practice. - Source: PubMed
Publication date: 2026/05/07
Alberti PaolaFaithfull SaraArgyriou Andreas ABalayssac DavidHertz Daniel LLustberg MaryamPark Susanna BLi TiffanyTanay MaryJabaley TerriWorthen-Chaudhari LiseSmith Ellen M L - Measuring plasma biomarkers effectively assesses early-stage Alzheimer's disease. - Source: PubMed
Boutajangout AllalMasurkar Arjun VOsorio RicardoDebure LudovicGhuman MobeenaAhmed WajihaVedvyas AlokPirraglia ElizabethLinks JonBokacheva LouisaVega BriannaBernard Mark AMarsh KarynBubu Omonigho MShao YongzhaoChodosh JoshuaRusinek HenryWisniewski Thomas